Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Recurrence

Esophageal Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Esophageal Squamous Cell Carcinoma

Testicular Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

All Drugs and Chemicals

Vaccines

Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides

vaccination

Koji Kono, PhD, MD

Kousaku Mimura, PhD. MD

The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

The phase II multicenter trial of vaccination study using peptides derived from URLC10, CDCA1, and KOC1 for locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) who had failed for the standard therapy are performed to evaluate the survival benefit of the cancer vaccination.

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens (STF-II) for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Human Genome Center, Institute of Medical Science, University of Tokyo

University of Yamanashi

First Department of Surgery

Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.

TTK, LY6K, and IMP-3 peptides

Koji Kono, M.D. & Ph.D.

Hideki Fujii, MD, PhD

Koji Kono, MD, PhD

Koji Kono, MD.PhD

The purpose of this study is to evaluate the safety and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

We recently identified three HLA-A2402-restricted epitope peptides (TTK protein kinase (TTK), lymphocyte antigen 6 complex locus K (LY6K), and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3)) derived from novel Cancer-Testis antigens (CTA) for the development of immunotherapies against esophageal squamous cell carcinoma (ESCC), and reported that the pre-existence of specific T cell responses to these epitope peptides were frequently seen in ESCC patients. Then, we performed Phase I vaccination trial using multi-epitopes involving TTK, LY6K, and IMP-3 peptides for locally advanced, recurrent or metastatic esophageal squamous cell carcinoma who had failed for the standard therapy. Each of three HLA-A2402-restricted epitope peptides mixed with IFA were injected every week at five round. Primary endpoints were to evaluate the safety and feasibility of the therapy. Secondary endpoints were to investigate the immunological monitoring and clinical effect.

Peptide Vaccination in Treating Patients With Esophageal Cancer

Phase I Study of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Koji Kono

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)	NCT01267578	Esophageal Canc...	vaccination	20 Years - 80 Years	University of Yamanashi
Peptide Vaccination in Treating Patients With Esophageal Cancer	NCT00682227	Esophageal Canc...	TTK, LY6K, and ...	20 Years - 80 Years	University of Yamanashi

Spots Global Cancer Trial Database for epitope peptide, ctl, esophageal cancer, vaccination